ReviewCannabidiol in medical marijuana: Research vistas and potential opportunities
Graphical abstract
Introduction
It is estimated that approximately 180 million people between the ages of 18–65 have self-administered marijuana at least once in their lifetime globally [1]. According to the Global Burden of Disease Study, it was estimated that approximately 13 million people worldwide are dependent on cannabis [2]. It has also been reported that the rates of cannabis consumption in the general population is increasing, particularly amongst younger populations (i.e. high school students) [3]. The anticipated legalization of marijuana in various countries and jurisdictions (e.g. USA, Canada) in 2017, with the accompanied commercial interest in the sale of cannabinoid-containing products (i.e. medical marijuana), is predicted to further increase cannabis utilization, inviting the need for rigorous safety and efficacy data.
The overarching aim of this article is to provide healthcare providers and other stakeholders with pragmatic data-driven decision support regarding the pharmacology and putative clinical applications of CBD. We have specifically chosen three of the most common mental health complaints wherein patients seek out advice related to the use of medical marijuana as a treatment (i.e., anxiety, depression, and sleep) [4]. We delimit our focus to CBD, an active moiety in medical marijuana; recent systematic reviews and meta-analyses provide replicable and convergent evidence of the hazardous effects of Δ9-THC [5], [6].
Section snippets
Methods
This is a narrative, non-systematic review of pre-clinical and clinical studies. An electronic literature search was conducted using the following databases: PubMed, PsychInfo, and Scopus from inception to November 2016. The search term cannabidiol was cross-referenced with the terms anxiety, depression, sleep, cannabis, and medical marijuana. We delimited our search to articles written in English that were published within the past ten years. Pharmacological, molecular, and physiologic studies
Conclusion
Despite rapid changes in the social, political, cultural and legal landscape, as well as the significant increase in cannabis utilization, there is insufficient decision support provided by available evidence regarding CBD. Taken together, Δ9-THC elicits adverse psychological and physiological effects amongst users, while CBD has unique pharmacologic, physiologic, and behavioural effects with suggestions of salutary effects on brain substrates subserving anxiety, mood and sleep complaints.
At
Key points
- 1)
High cannabis consumption in the Canadian general population and increasing.
- 2)
Federal decriminalization expected to further increase consumption.
- 3)
Preponderance of data indicates that Δ9-THC is deleterious to brain function and behaviour.
- 4)
Extant data regarding cannabidiol (CBD) indicates that CBD may exert salutary effects on brain mechanisms implicated as abnormal in some psychopathological states.
Potential neurotherapeutic effects of cannabidiol:
- •
antipsychotic
- •
antidepressive
- •
antianxiety/anxiolytic
- •
References (45)
- et al.
Endocannabinoid system and mood disorders: priming a target for new therapies
Pharmacol. Ther.
(2013) - et al.
Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors
Pharmacol. Ther.
(2011) - et al.
Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings
Addict. Behav.
(2013) - et al.
The use of cognitive enhancers in animal models of fear extinction
Pharmacol. Biochem. Behav.
(2011) - et al.
The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project
Compr. Psychiatry
(2015) - et al.
Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors
Neuropharmacology
(2016) - et al.
The effects of cannabinoid administration on sleep: a systematic review of human studies
Sleep Med. Rev.
(2014) World drug report 2013 by united nations office on drugs and crime new York: PB − united nations, 2013ISBN: 978-92-1-056168-6, 151 pp. grey literature
Drug Alcohol Rev.
(2014)- et al.
The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study
PLoS One
(2013) - et al.
Marijuana use predicts cognitive performance on tasks of executive function
J. Stud. Alcohol Drugs
(2016)